Premium
High‐dose chemotherapy with busulphan and cyclophosphamide and bone‐marrow transplantation for drug‐sensitive malignancies in adults: a preliminary report
Author(s) -
Sheridan William P.,
Boyd Andrew W.,
Green Michael D.,
Russell David M.R.,
Thomas Robert J.S.,
McGrath Katherine M.,
Vaughan Stephen L.,
Scarlett John D.,
Griffiths James D.,
Brodie Graeme N.,
Januszewicz E. Henry,
Fox Richard M.
Publication year - 1989
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1989.tb101219.x
Subject(s) - medicine , cyclophosphamide , chemotherapy , bone marrow , busulfan , surgery , methotrexate , oncology
The technique of high‐dose chemotherapy and bone‐marrow transplantation takes advantage of any potential dose–response effect in the treatment of cancer and the ability of infused marrow to circumvent severe myelotoxicity. We report our initial experience of 20 high‐dose chemotherapy procedures with busulphan and cyclophosphamide as the treatment regimen. Autologous (14 patients), human leukocyte antigen‐matched, sibling‐allogeneic (five patients) and identical‐twin (one patient) transplantations were performed in patients with leukaemias (12 patients), lymphomas (seven patients) or a germ‐cell tumour (one patient). One in‐hospital and one late death occurred as a result of the toxicity of high‐dose chemotherapy. All evaluable patients demonstrated bone‐marrow engraftment and became independent of blood transfusions. Five of six patients who were treated in partial remission or relapse obtained a complete remission. Seven patients have relapsed. Eleven patients currently are alive and disease‐free and nine patients have returned to their full‐time occupations. High‐dose chemotherapy can be undertaken with an over‐all morbidity that is similar to that which is experienced during the induction chemotherapy of acute leukaemia.